BioTelemetry, Inc. (NASDAQ:BEAT) is scheduled to be posting its quarterly earnings results after the market closes on Monday, July 31st. Analysts expect BioTelemetry to post earnings of $0.21 per share for the quarter.
BioTelemetry (NASDAQ:BEAT) last announced its quarterly earnings results on Wednesday, May 3rd. The medical research company reported $0.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.02. The company had revenue of $55.88 million for the quarter, compared to analyst estimates of $55.11 million. BioTelemetry had a net margin of 22.77% and a return on equity of 19.87%. On average, analysts expect BioTelemetry to post $0.88 EPS for the current fiscal year and $1.14 EPS for the next fiscal year.
Shares of BioTelemetry, Inc. (NASDAQ:BEAT) opened at 34.80 on Friday. The company has a market capitalization of $997.19 million, a price-to-earnings ratio of 21.74 and a beta of 0.76. The company’s 50 day moving average is $32.19 and its 200 day moving average is $28.37. BioTelemetry, Inc. has a one year low of $15.25 and a one year high of $35.75.
TRADEMARK VIOLATION WARNING: “BioTelemetry, Inc. (BEAT) Set to Announce Earnings on Monday” was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://stocknewstimes.com/2017/07/29/biotelemetry-inc-beat-set-to-announce-earnings-on-monday.html.
Several research analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of BioTelemetry from a “hold” rating to a “buy” rating and set a $38.00 target price on the stock in a report on Tuesday, May 2nd. Dougherty & Co lifted their price target on shares of BioTelemetry from $30.00 to $37.00 and gave the company a “buy” rating in a report on Tuesday, April 11th. BidaskClub cut shares of BioTelemetry from a “strong-buy” rating to a “buy” rating in a report on Tuesday. Lake Street Capital reiterated a “buy” rating and issued a $50.00 price target (up previously from $35.00) on shares of BioTelemetry in a report on Friday, July 14th. Finally, Benchmark Co. lifted their price target on shares of BioTelemetry from $38.00 to $44.00 and gave the company a “buy” rating in a report on Wednesday, July 19th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $39.20.
In related news, Director Robert J. Rubin sold 15,000 shares of BioTelemetry stock in a transaction on Monday, May 15th. The shares were sold at an average price of $28.14, for a total value of $422,100.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 9.60% of the company’s stock.
About BioTelemetry
BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.
Receive News & Ratings for BioTelemetry Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
